找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Immunotherapy; Aung Naing,Joud Hajjar Book 20203rd edition The Editor(s) (if applicable) and The Author(s), under exclusive license to Spr

[復(fù)制鏈接]
樓主: CHAFF
31#
發(fā)表于 2025-3-27 00:18:03 | 只看該作者
Hepatobiliary Adverse Events,city of ICI therapy. Appropriate treatment of pancreatitis still needs further investigation. Few cases, reports, and series documented cholecystitis and cholangitis as possible adverse events related to ICI therapy as well.
32#
發(fā)表于 2025-3-27 02:36:00 | 只看該作者
Cancer Imaging in Immunotherapy,g therapies, including immunotherapies, still relies on the current RECIST criteria. In this chapter, we review the traditional and new imaging response criteria for evaluation of solid tumors and briefly touch on some of the more commonly associated immunotherapy-induced adverse events.
33#
發(fā)表于 2025-3-27 08:27:10 | 只看該作者
34#
發(fā)表于 2025-3-27 12:05:48 | 只看該作者
35#
發(fā)表于 2025-3-27 17:23:54 | 只看該作者
36#
發(fā)表于 2025-3-27 20:28:24 | 只看該作者
37#
發(fā)表于 2025-3-27 22:13:00 | 只看該作者
Gastrointestinal Tract Adverse Events,ysical examination, stool tests, endoscopic and histologic evaluation, and/or imaging. Current management strategy is mainly anti-diarrheal agents for mild symptoms and immunosuppressants (e.g., corticosteroids, and infliximab or vedolizumab) for more severe diseases.
38#
發(fā)表于 2025-3-28 02:16:19 | 只看該作者
Renal Toxicity,mmune diseases and focus on renal cell cancer in setting of Chronic kidney disease (CKD). Transplant rejection in the setting of CPI use is yet to be further studied, and available data is presented in this chapter.
39#
發(fā)表于 2025-3-28 06:31:01 | 只看該作者
40#
發(fā)表于 2025-3-28 12:03:59 | 只看該作者
Advances in Diagnostic Procedures and Their Applications in the Era of Cancer Immunotherapy,n immunotherapy: immunohistochemistry, next-generation sequencing, and flow cytometry. We also describe the uses of other diagnostic procedures and preclinical animal models in cancer immunotherapy translational research.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-2-7 07:37
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
曲松县| 北安市| 崇仁县| 天门市| 金沙县| 凤阳县| 泽州县| 虎林市| 荔波县| 乌兰察布市| 犍为县| 铜鼓县| 德令哈市| 钟山县| 福清市| 阳东县| 仙居县| 益阳市| 于田县| 张家口市| 南川市| 西宁市| 台中市| 晴隆县| 高雄县| 晋江市| 苍南县| 龙川县| 兰溪市| 安达市| 衡水市| 长岛县| 南阳市| 内江市| 嘉定区| 泰州市| 开鲁县| 绥滨县| 巴楚县| 卓尼县| 新和县|